Monthly Schizophrenia Treatment Cost 20%-30% Lower With First-Generation Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Catie research published in the American Journal of Psychiatry shows that treatment with older drugs may be less expensive but just as effective.
You may also be interested in...
Zyprexa Could Gain From CATIE Cost/Benefit Analysis, Lilly Says
Forthcoming cost-effectiveness analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness study could prove to be a boon for Zyprexa because of reduced hospitalization with Lilly’s atypical antipsychotic.
Zyprexa Reduced Hospitalization Rate In CATIE Study Is Key For Payors, Lilly Says
U.S. sales of the antipsychotic fell 10% in the third quarter; CATIE trial results will not boost Zyprexa sales "overnight," COO Lechleiter says.
Zyprexa Ekes Out Narrow Lead In Schizophrenia Study, But Efficacy Is Offset By Side Effects
CATIE study finds no significant difference in effectiveness between conventional antipsychotic perphenazine and three atypicals: AstraZeneca’s Seroquel, J&J’s Risperdal and Pfizer’s Geodon.